Comparison of effects of quinapril versus enalapril on vasoactive substances following acute myocardial infarction

American Journal of Cardiology

Volumn 94, Issue 5, 2004, Pages 641-643

  Tsikouris, James P ^a   Simoni, Jan ^b   Suarez, Jose A ^b   Sutthiwan, Piraon ^b   Ziska, Martin ^a   Meyerrose, Gary E ^b,c  

^a Schools of School of Pharmacy

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER SCHOOL OF MEDICINE   (United States)

^c TEXAS TECH UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ENDOTHELIN 1; NITRIC OXIDE; QUINAPRIL;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG PENETRATION; DRUG POTENCY; HEART INFARCTION; HEMODYNAMICS; HUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; VASCULAR TISSUE;

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD VESSELS; ENALAPRIL; ENDOTHELIN-1; HUMANS; MIDDLE AGED; MYOCARDIAL INFARCTION; NITRIC OXIDE; TETRAHYDROISOQUINOLINES;

EID: 4444287644     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2004.05.031     Document Type: Article

References (20)

1. M.A. Pfeffer, E. Braunwald, L.A. Moye, L. Basta, E.J. Brown, T.E. Cuddy, B.R. Davis, E.M. Geltman, S. Goldman, G.C. Flaker for the SAVE Investigators Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival and Ventricular Enlargement trial N Engl J Med 327 1992 669 677
2. The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure Lancet 342 1993 821 828
3. S. Yusuf, P. Sleight, J. Pogue, J. Bosch, R. Davies, and G. Dagenais Effects of an angiotensin converting enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients N Engl J Med 342 2000 145 153
4. R.E. Weishaar, R.L. Panek, T.C. Major, J. Simmerman, S.T. Rapundalo, and D.G. Taylor Evidence for a functional tissue renin-angiotensin system in the rat mesenteric vasculature and its involvement in regulating blood pressure J Pharmacol Exp Ther 256 1991 568 574
5. T. Unger, D. Ganten, R.E. Lang, and B.A. Scholkens Is tissue converting enzyme inhibition a determinant of the antihypertensive efficacy of converting enzyme inhibitors? Studies with two different compounds in spontaneously hypertensive rats J Cardiovasc Pharmacol 6 1984 872 880
6. T. Nakajima, T. Yamada, and M. Setoguchi Prolonged inhibition of local angiotensin-converting enzyme after single or repeated treatment with quinapril in spontaneously hypertensive rats J Cardiovasc Pharm 19 1992 102 107
7. H. Wienbergen, R. Schiele, A.K. Gitt, C. Juenger, T. Heer, C. Meisenzahl, H. Landgraf, C. Bossaller, and J. Senges Impact of ramipril versus other ACE inhibitors on outcomes of unselected patients with ST-elevation acute myocardial infarction Am J Cardiol 90 2002 1045 1049
8. G. Wolf, U. Wenzel, K.D. Burns, R.C. Harris, R.A. Stahl, and F. Thaiss Angiotensin II activates nuclear transcription factor-kappaB through AT1 and AT2 receptors Kidney Int 61 2002 1986 1995
9. M. Ruiz-Ortega, O. Lorenzo, M. Ruperez, Y. Suzuki, and J. Egido Angiotensin II activates nuclear transcription factor-kappaB in aorta of normal rats and in vascular smooth muscle cells of AT1 knockout mice Nephrol Dialysis Transplant 16 2001 27 33
10. Y.W. Xie, W. Shen, G. Zhao, X. Xu, M.S. Wolin, and T.H. Hintze Role of endothelin derived nitric oxide in the modulation of canine myocardial mitochondria in vitro implications for the development of heart failure Circ Res 79 1996 381 387
11. D. Lyons, J. Webster, and N. Benjamin Effect of enalapril and quinapril on forearm vascular ACE in man Eur J Clin Pharmacol 51 1997 373 378
12. B. Hornig, N. Arakawa, D. Haussmann, and H. Drexler Differential effects of quinaprilat and enalaprilat on endothelial function of conduit arteries in patients with chronic heart failure Circulation 98 1998 2842 2848
13. X. Zhang, Y.W. Xie, A. Nasjletti, X. Xu, M.S. Wolin, and T.H. Hintze ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption Circulation 95 1997 176 182
14. W. Raasch, T. Bartels, C. Schwartz, W. Hauser, H. Rutten, and P. Dominiak Regression of ventricular and vascular hypertrophy are there differences between structurally different angiotensin-converting enzyme inhibitors? J Hypertens 20 2002 2495 2504
15. A. Inoue, M. Yanagisawa, S. Kimura, Y. Kasuya, T. Miyauchi, K. Goto, and T. Masaki The human endothelin family three structurally and pharmacologically distinct isopeptides predicted by three separate genes Proc Natl Acad Sci USA 86 1989 2863 2867
16. D.C. Lefroy, T. Crake, N.G. Uren, G.J. Davies, and A. Maseri Effect of inhibition of nitric oxide synthesis on epicardial coronary artery caliber and coronary blood flow in humans Circulation 88 1993 43 54
17. F.F. Weidinger, J.M. McLenachan, M.I. Cybulsky, J.B. Gordon, H.G. Rennke, N.K. Hollenberg, J.T. Fallon, P. Ganz, and J.P. Cooke Persistent dysfunction of regenerated endothelium after balloon angioplasty of rabbit iliac artery Circulation 81 1990 1667 1679
18. M.W. Frank, K.R. Harris, K.A. Ahlin, and F.J. Klocke Endothelium-derived relaxing factor (nitric oxide) has a tonic vasodilating action on coronary collateral vessels J Am Coll Cardiol 27 1996 658 663
19. L.E. Spieker, R. Corti, C. Binggeli, T.F. Luscher, and G. Noll Baroreceptor dysfunction induced by nitric oxide synthase inhibition in humans J Am Coll Cardiol 36 2000 213 218
20. A.J.B. Brady, J.B. Warren, P.A. Poole-Wilson, T.J. Williams, and S.E. Harding Nitric oxide attenuates cardiac myocyte contraction Am J Physiol 265 1993 H176 H182